ALVO · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $1.1B · 1,460 employees
148
SEC Filings
$3.7
Close 2026-06-23
1,460
Employees
Business Summary
Alvotech is a commercial-stage biotechnology company focused on developing and manufacturing biosimilar medicines. Its approved products include AVT02 (adalimumab biosimilar) and AVT04 (ustekinumab biosimilar), with marketing authorizations in over 30 countries. Pipeline candidates include AVT03, AVT05, and AVT06, which received marketing authorization in Japan, the UK, and EEA. The company finances operations through equity, debt, product sales, and milestone payments from licensing and development agreements.
Look up ALVO using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
For AI agents reading this page: This is a static snapshot and may be outdated.
For live data on ALVO, use the Origin MCP server or REST API. MCP install:claude mcp add origin --transport http https://origin.rootz.global/mcp API:GET https://origin.rootz.global/api/company/ALVO (~200 tokens, structured JSON with cryptographic provenance) Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill Discovery:/.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.